Quick answer: Semax side effects on the Russian label are limited to one item: mild irritation of the nasal lining with long-term use.[1] That sounds reassuring, but most human studies did not report safety at all, and FDA found too little data to describe its safety profile.[3] Known concerns include abnormal EEG activity after a dose in some brain-injured patients,[5] plus theoretical risks of bleeding, immune reactions and misuse. Semax is not FDA-approved.
Below is what each source actually reported, who should avoid Semax, and what is still unknown. For the full research picture, see our Semax profile or browse the nootropic peptides hub.
Semax side effects on the Russian label
Both Russian labels, for the 0.1% and 1% nasal drops, list a single side effect: possible mild irritation of the nasal mucosa with prolonged use.[1][2]
The labels also make claims from animal testing: that Semax is practically non-toxic with single and repeated doses and does not irritate tissue locally.[1] These are manufacturer statements in the label, not results from large human safety trials.
What human studies reported
The evidence base is small. FDA counted roughly 33 to 47 healthy adults, 69 adults with medical conditions and 451 children in the Semax studies it reviewed.[3] Its main findings:
- Most papers did not mention safety. Of the studies FDA summarized, only one reported on side effects at all, and its authors said they saw none. The rest did not discuss adverse events.[3]
- Several gave Semax with other treatments, which makes it hard to tell which drug caused what.[3]
- Three were meeting abstracts, so full details were not available, including for the 451 children.[3]
Other Russian studies add a little:
| Study | People | What was reported about safety |
|---|---|---|
| Cerebrovascular insufficiency, 2005 | 187 patients | The authors described a “minor percent” of side effects and good tolerability, including in older patients, without listing them in the abstract[4] |
| Brain injury after oxygen loss, 1999 | 73 patients | Some had episodes of paroxysmal (seizure-like) EEG activity after Semax; the authors advised giving the first dose with EEG monitoring[5] |
| Motor neuron disease (ALS), 2007 | 27 patients, two 10-day courses of 12 mg/day | Safety not described in the abstract; quality of life improved, disease scores did not change[7] |
EEG changes and seizure risk
The 1999 EEG finding is the most specific human safety signal. It came from patients who already had brain damage after a period without enough oxygen, a group at higher risk of seizures.[5] It does not tell us how often this happens in healthy people. The Russian labels list a history of seizures as a contraindication.[1][2]
FDA’s 2026 safety concerns
FDA reviewed Semax in 2026 when deciding whether pharmacies could compound it. Its staff raised several concerns:[3]
- Bleeding: a Russian abstract suggested Semax has anti-clotting effects, which FDA said raises concern for people at risk of bleeding or taking other drugs that increase bleeding risk.
- Immune reactions: peptides can trigger antibodies, and FDA was concerned about clumping and impurities in injected or sprayed products. No study has checked this for Semax.
- Abuse potential: in mice, Semax increased dopamine release triggered by amphetamine in a brain area linked to drugs of abuse. No study has tested whether Semax itself is habit-forming.
- Cancer: the only long-term study was in a mouse strain prone to tumors and was not designed to test cancer risk. No standard 2-year cancer study exists.
- One adverse event report: a consumer reported eye pain and burning after using Semax 0.1% drops bought online, was hospitalized, and still had eye pain a year later.
FDA lists Semax among bulk substances that may pose significant safety risks in compounding.[8] Even so, in July 2026 its advisory committee voted 8 to 5 to recommend allowing Semax in compounding, against FDA staff advice. FDA has not issued a final decision.[10]
Anxiety and overstimulation
Semax is usually described as stimulating rather than calming. The label’s contraindications include “disorders accompanied by anxiety” and acute psychiatric conditions,[1] so people with anxiety disorders are told not to use it. In rodents, Semax raised serotonin turnover and strongly boosted amphetamine-driven dopamine release and activity.[6] That is one reason to be cautious about combining it with stimulant ADHD medicines, although this has not been studied in people.
Who should not use Semax
The Russian labels say not to use Semax if you have:[1][2]
- an acute psychiatric condition or a disorder accompanied by anxiety
- a history of seizures
- pregnancy or are breastfeeding (no clinical studies were done)
- a child under 7 for the 0.1% product, or anyone under 18 for the 1% product or eye and neurosurgical uses
- an allergy to any ingredient
The label also advises against using decongestant nasal sprays at the same time.[1] Based on FDA’s concerns, people with a bleeding disorder or who take blood thinners should raise this with a clinician first.[3]
Extra risks with products bought online
Russian Semax is a licensed medicine in drops. Most Semax sold in the US is not. Belgian regulators found Semax in seized unlabeled products and noted that these peptides are sold online as powders for injection or in nasal sprays.[9] FDA found no safety data for injected Semax at all.[3] With an unregulated product, the dose, purity and sterility are unknown, which adds risks that the Russian studies never measured. Our Semax nasal spray guide covers the difference between licensed drops and sprays sold online.
Questions to ask your clinician
- Do I have anything on the label’s do-not-use list, such as anxiety, seizures or pregnancy?
- Could Semax interact with my stimulant, blood thinner or other medicines?
- What symptoms should make me stop, such as sleep problems, agitation or nosebleeds?
- Is there an approved treatment with better safety data for my condition?
If you have a side effect after using any unapproved product, you can report it to FDA through MedWatch, which FDA encourages for compounded drugs.[3]
